| Identification | Back Directory | [Name]
tert-Butyl 3,5-bis(2-fluorobenzylidene)-4-oxopiperidine-1-carboxylate | [CAS]
939681-36-4 | [Synonyms]
G5-7
tert-Butyl 3,5-bis(2-fluorobenzylidene)-4-oxopiperidine-1-carboxylate
1-Piperidinecarboxylic acid, 3,5-bis[(2-fluorophenyl)methylene]-4-oxo-, ethyl ester
antiangiogenic,inhibit,Apoptosis,JAK,Glioma,G-5-7,cycle,G5 7,phase,G57,STAT3,cell,Inhibitor,EGFR,Janus kinase,G5-7,mTOR | [Molecular Formula]
C22H19F2NO3 | [MOL File]
939681-36-4.mol | [Molecular Weight]
383.39 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 83.33 mg/mL (217.35 mM; Need ultrasonic) | [form ]
Solid | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study[1]. | [in vivo]
G5-7 (10 and 50 mg/kg, oral gavege) decreases VEGF secretion and exerts a potent antiangiogenic effect[1].
| Animal Model: | Cells (4 × 106) in 100 μl of serum-free DMEM were inoculated subcutaneously into 5- to 6-week-old female nude mice[1].
| | Dosage: | 10 and 50 mg/kg. | | Administration: | Oral gavage. | | Result: | Suppresses angiogenesis in tumors. |
| [IC 50]
JAK2 | [storage]
Store at -20°C | [References]
[1] Kunyan He, et al. Blockade of glioma proliferation through allosteric inhibition of JAK2. Sci Signal. 2013 Jul 9;6(283):ra55. DOI:10.1126/scisignal.2003900 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|